Download Free From Biotechnology To Bioindustry Book in PDF and EPUB Free Download. You can read online From Biotechnology To Bioindustry and write the review.

전 세계 주요국들에서 보건의료, 에너지, 환경 분야는 국가 안보와도 밀접하게 연결되어 있는 만큼 중점 사업으로 막대한 투자를 아끼지 않고 있다. 이에 힘입어 이들 분야 산업은 급속히 성장하고 있는데, 생명공학 기술, 정보통신 기술, 나노 기술, 에너지·환경 기술, 우주 기술 등이 대표적이다. 현재 각 분야 간의 융합이 이루어져 새로운 기술들을 속속 선보이고 있으며, 특히 생명공학 기술은 이러한 융합 기술을 창조하는 데 매우 중요한 역할을 하고 있다. 생명공학 기술을 바탕으로 바이오 산업은 지속적으로 성장하고 있으며, 바이오 경제도 활성화되고 있다. 따라서 기본적인 생명공학 기술과 다양한 바이오 산업을 이해하는 것은 현대를 살아가는 우리에게 매우 중요하지 않을 수 없다. 이 책에서는 생명공학 기술이 어떻게 바이오 산업에 응용되는가를 교양 수준에서 알기 쉽게 서술하였다.
Publisher Description
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
Providing the first overview of Asia’s emerging biosciences landscape, this timely and important collection brings together ethnographic case studies on biotech endeavors such as genetically modified foods in China, clinical trials in India, blood collection in Singapore and China, and stem-cell research in Singapore, South Korea, and Taiwan. While biotech policies and projects vary by country, the contributors identify a significant trend toward state entrepreneurialism in biotechnology, and they highlight the ways that political thinking and ethical reasoning are converging around the biosciences. As ascendant nations in a region of postcolonial emergence, with an “uncanny surplus” in population and pandemics, Asian countries treat their populations as sources of opportunity and risk. Biotech enterprises are allied to efforts to overcome past humiliations and restore national identity and political ambition, and they are legitimized as solutions to national anxieties about food supplies, diseases, epidemics, and unknown biological crises in the future. Biotechnological responses to perceived risks stir deep feelings about shared fate, and they crystallize new ethical configurations, often re-inscribing traditional beliefs about ethnicity, nation, and race. As many of the essays in this collection illustrate, state involvement in biotech initiatives is driving the emergence of “biosovereignty,” an increasing pressure for state control over biological resources, commercial health products, corporate behavior, and genetic based-identities. Asian Biotech offers much-needed analysis of the interplay among biotechnologies, economic growth, biosecurity, and ethical practices in Asia. Contributors Vincanne Adams Nancy N. Chen Stefan Ecks Kathleen Erwin Phuoc V. Le Jennifer Liu Aihwa Ong Margaret Sleeboom-Faulkner Kaushik Sunder Rajan Wen-Ching Sung Charis Thompson Ara Wilson
The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.
The latest volume in the Advanced Biotechnology series provides an overview of the main product classes and platform chemicals produced by biotechnological processes today, with applications in the food, healthcare and fine chemical industries. Alongside the production of drugs and flavors as well as amino acids, bio-based monomers and polymers and biofuels, basic insights are also given as to the biotechnological processes yielding such products and how large-scale production may be enabled and improved. Of interest to biotechnologists, bio and chemical engineers, as well as those working in the biotechnological, chemical, and food industries.
In her quest for a global leadership in science and technology, the People's Republic of China has attained top ranks in the number of scientific publications, "hot papers," or national and international patent applications. This also pertains to fields such as biomedicine, agricultural and industrial biotechnology, as well as environmental monitoring and sanitation. However, analysis of the underlying structures and mechanisms is hindered by the sheer flood of data, by stringent government control of all media, including the internet; and by ambiguities inherent in translation from Chinese. This book tries to overcome these difficulties and provides a concise picture of the biotechnology-related research and development (R&D) in China. The book begins with brief accounts of China's geography, people, and their mindset; her political and administrational structure, economy, and finance; her infrastructure related to science and technology; and her educational system and R&D landscape. It then presents succinct accounts on structures and developments in biomedicine, diagnostics, agriculture, fermented food, bioindustry, and environmental biotechnology, with reference to government, industry, and academia. It finally attempts to predict next steps in Chinese biotechnology, both for the national agenda and in view of China's ambitious global development strategy, the Belt and Road Initiative.
Pharmaceutical Biotechnology offers students taking Pharmacy and related Medical and Pharmaceutical courses a comprehensive introduction to the fast-moving area of biopharmaceuticals. With a particular focus on the subject taken from a pharmaceutical perspective, initial chapters offer a broad introduction to protein science and recombinant DNA technology- key areas that underpin the whole subject. Subsequent chapters focus upon the development, production and analysis of these substances. Finally the book moves on to explore the science, biotechnology and medical applications of specific biotech products categories. These include not only protein-based substances but also nucleic acid and cell-based products. introduces essential principles underlining modern biotechnology- recombinant DNA technology and protein science an invaluable introduction to this fast-moving subject aimed specifically at pharmacy and medical students includes specific ‘product category chapters’ focusing on the pharmaceutical, medical and therapeutic properties of numerous biopharmaceutical products. entire chapter devoted to the principles of genetic engineering and how these drugs are developed. includes numerous relevant case studies to enhance student understanding no prior knowledge of protein structure is assumed
Bill Gates recently told Wired that if he were a teenager today, he would be hacking biology. "If you want to change the world in some big way," he says, "that's where you should start-biological molecules." The most disruptive force on the planet resides in DNA. Biotech companies and academic researchers are just beginning to unlock the potential of piecing together life from scratch. Champions of synthetic biology believe that turning genetic code into Lego-like blocks to build never-before-seen organisms could solve the thorniest challenges in medicine, energy, and environmental protection. But as the hackers who cracked open the potential of the personal computer and the Internet proved, the most revolutionary discoveries often emerge from out-of-the-way places, forged by brilliant outsiders with few resources besides boundless energy and great ideas. In Biopunk, Marcus Wohlsen chronicles a growing community of DIY scientists working outside the walls of corporations and universities who are committed to democratizing DNA the way the Internet did information. The "biohacking" movement, now in its early, heady days, aims to unleash an outbreak of genetically modified innovation by making the tools and techniques of biotechnology accessible to everyone. Borrowing their idealism from the worlds of open-source software, artisinal food, Internet startups, and the Peace Corps, biopunks are devoted advocates for open-sourcing the basic code of life. They believe in the power of individuals with access to DNA to solve the world's biggest problems. You'll meet a new breed of hackers who aren't afraid to get their hands wet, from entrepreneurs who aim to bring DNA-based medical tools to the poorest of the poor to a curious tinkerer who believes a tub of yogurt and a jellyfish gene could protect the world's food supply. These biohackers include: -A duo who started a cancer drug company in their kitchen -A team who built an open-source DNA copy machine -A woman who developed a genetic test in her apartment for a deadly disease that had stricken her family Along with the potential of citizen science to bring about disruptive change, Wohlsen explores the risks of DIY bioterrorism, the possibility of genetic engineering experiments gone awry, and whether the ability to design life from scratch on a laptop might come sooner than we think.
A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models. JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE “Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can–and must–apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system.” BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM “Simon and Giovannetti have written an essential user’s manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds.” EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB “If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about.” JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS “Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today’s innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book.”